We commenced operations in August 2008. Our corporate website address is www.evaxion.ai. The information on, or that can be accessed through, our website is not part of and should not be incorporated by reference into this annual report or any other report we file or furnish to the U.S.
skin and soft tissue infections (S. aureus)(Preclinical)
Status note Preclinical; potential prophylactic and therapeutic use.
EVX-B2
Preclinical · ActiveModality: vaccine
Target N. gonorrhoeae antigens
Partnerships Afrigen (collaboration)
Indications
gonorrhea(Preclinical)
Status note Preclinical proof of concept.
EVX-B3
Stage not disclosed · ActiveModality: vaccine
Partnerships MSD (Merck & Co., Rahway, NJ; licensed 2025 for $7.5M; Evaxion eligible for development, regulatory and sales milestones and royalties on net sales)
Indications
undisclosed bacterial pathogen(Stage not disclosed)
Status note Licensed to MSD for $7.5M upfront in 2025; Evaxion eligible for future development, regulatory and sales milestones and royalties.
EVX-B4
Preclinical · ActiveModality: vaccine
Target Group A Streptococcus antigens
Indications
Group A Streptococcus infection(Preclinical)
Catalysts
— H2 2026
Status note Preclinical.
EVX-V1
Stage not disclosed · ActiveModality: multi-component prophylactic vaccine
Target CMV antigens
Indications
cytomegalovirus (CMV) infection (e.g., solid organ transplant)(Stage not disclosed)
Status note Stage not stated in filing.
Per-asset detail extracted from the 20-F filed 2026-03-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.